Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of DS102 (epeleuton) in severe acute decompensated alcoholic hepatitis
2018-000819-25Phase 2Terminated
- Sponsor
- Afimmune
- Start
- Dec 2018
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in alcoholic hepatitis (AH) comparing DS102 (epeleuton) with Placebo (2 arms). Primary endpoint: Percentage change in MELD score from baseline to Day 28. Started Dec 2018; status: terminated.
02
Drugs
epeleuton
03
Conditions
alcoholic hepatitis (AH)
Beyond the preview
Go deeper on 2018-000819-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000819-25.